Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research[1][2][3].
Dasiglucagon PK profile shows a dose-dependent and rapid increase in plasma levels[2].
| Dasiglucagon dose | ||||
| 0.1 mg | 0.3 mg | 0.6 mg | 1.0 mg | |
| N | 5 | 16 | 16 | 16 |
| AUC0-30min (pmol*h/L) | 99.4 (32.0) | 302 (78.9) | 444 (163) | 884 (307) |
| AUC0-360min (pmol*h/L) | 451 (123) | 1360 (166) | 1630 (368) | 4800 (697) |
| AUC0-inf (pmol*h/L) | 451 (123) | 1360 (166) | 2640 (365) | 4810 (696) |
| Cmax (pmol/L) | 334 (113) | 976 (208) | 1570 (445) | 2800 (767) |
| tmax (h) | 0.50 (0.5-0.6) | 0.63 (0.3-0.8) | 0.58 (0.5-1.7) | 0.63 (0.3-0.8) |
| t1/2 (h) | 0.43 (0.07) | 0.43 (0.07) | 0.49 (0.14) | 0.54 (0.17) |
[1]. Bo Xu, et al. Dasiglucagon: an effective medicine for severe hypoglycemia. Eur J Clin Pharmacol. 2021 Dec;77(12):1783-1790.
[2]. Ulrike HÖvelmann, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018 Mar;41(3):531-537.
[3]. Yongjing Ju, et al. Dasiglucagon for treating severe hypoglycemia in patients with diabetes. Expert Rev Clin Pharmacol. 2022 Jul;15(7):799-803.